[go: up one dir, main page]

WO2013123840A1 - 抗肿瘤的氮杂苯并[f]薁衍生物其制备方法及其用途 - Google Patents

抗肿瘤的氮杂苯并[f]薁衍生物其制备方法及其用途 Download PDF

Info

Publication number
WO2013123840A1
WO2013123840A1 PCT/CN2013/070919 CN2013070919W WO2013123840A1 WO 2013123840 A1 WO2013123840 A1 WO 2013123840A1 CN 2013070919 W CN2013070919 W CN 2013070919W WO 2013123840 A1 WO2013123840 A1 WO 2013123840A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
cancer
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2013/070919
Other languages
English (en)
French (fr)
Chinese (zh)
Inventor
吴希罕
符立梧
张冬梅
王玉蓉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TIANYI BIOSCIENCE CO Ltd
Original Assignee
TIANYI BIOSCIENCE CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TIANYI BIOSCIENCE CO Ltd filed Critical TIANYI BIOSCIENCE CO Ltd
Priority to EP13751374.3A priority Critical patent/EP2818171B1/de
Priority to US14/380,596 priority patent/US9382249B2/en
Priority to ES13751374.3T priority patent/ES2617965T3/es
Priority to JP2014557981A priority patent/JP5851053B2/ja
Publication of WO2013123840A1 publication Critical patent/WO2013123840A1/zh
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • Compound 1-2 is named: 9 - (2-chlorophenyl)-6-ethyl-1-methyl-2-, 4-dihydro-2, 3, 4, 7, 10-pentaza-benzo [f]Made.
  • the compound (I) of the present invention can be produced by the following method:
  • the compounds of the invention all have excellent antitumor activity, IC 5 .
  • the value is between 0. 03-12. 6.
  • the compounds of the invention are useful in the preparation of a medicament for the treatment of neoplastic diseases.
  • the following are pharmacodynamic tests and results of some of the compounds of the present invention.
  • the structural formulas of the compounds 1-1 and 1-3 are shown in the examples.
  • Table 2 The tumor inhibition rate of each group of nude mice after drug treatment
  • Cyclophosphamide group 8 100 mg/kg 39.5 0.0395
  • Table 3 The tumor inhibition rate of each group of nude mice after drug treatment

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PCT/CN2013/070919 2012-02-24 2013-01-24 抗肿瘤的氮杂苯并[f]薁衍生物其制备方法及其用途 Ceased WO2013123840A1 (zh)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP13751374.3A EP2818171B1 (de) 2012-02-24 2013-01-24 Antitumor-aza-benzo-[f]-azulenderivat, verfahren zur herstellung davon und verwendung davon
US14/380,596 US9382249B2 (en) 2012-02-24 2013-01-24 Antitumor aza-benzo [f] azulen derivative, method for preparing same, and use thereof
ES13751374.3T ES2617965T3 (es) 2012-02-24 2013-01-24 Derivado de aza-benzo [f] azuleno antitumoral, método para su preparación, y su uso
JP2014557981A JP5851053B2 (ja) 2012-02-24 2013-01-24 抗腫瘍性アザベンゾ［ｆ］アズレン誘導体およびその製造方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201210043316.XA CN102603743B (zh) 2012-02-24 2012-02-24 抗肿瘤的氮杂苯并[f]薁衍生物其制备方法及其用途
CN201210043316.X 2012-02-24

Publications (1)

Publication Number Publication Date
WO2013123840A1 true WO2013123840A1 (zh) 2013-08-29

Family

ID=46521573

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2013/070919 Ceased WO2013123840A1 (zh) 2012-02-24 2013-01-24 抗肿瘤的氮杂苯并[f]薁衍生物其制备方法及其用途

Country Status (6)

Country Link
US (1) US9382249B2 (de)
EP (1) EP2818171B1 (de)
JP (1) JP5851053B2 (de)
CN (1) CN102603743B (de)
ES (1) ES2617965T3 (de)
WO (1) WO2013123840A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102603743B (zh) 2012-02-24 2014-05-28 南京天易生物科技有限公司 抗肿瘤的氮杂苯并[f]薁衍生物其制备方法及其用途
RS66947B1 (sr) * 2016-12-13 2025-07-31 Transthera Sciences Nanjing Inc Jedinjenje inhibitora više kinaza, i njegova kristalna forma i upotreba
CN109020980B (zh) * 2017-06-09 2020-11-20 华东师范大学 一类抗肿瘤作用的吡唑并嘧啶二氮*衍生物
US10611857B2 (en) 2017-08-02 2020-04-07 Exxonmobil Chemical Patents Inc. Bisphenolate transition metal complexes, production and use thereof
CA3172795A1 (en) * 2020-02-24 2021-09-02 Transthera Sciences (Nanjing), Inc. Novel use of multi-kinase inhibitor
AU2021267622A1 (en) * 2020-05-08 2022-12-15 Transthera Sciences (Nanjing), Inc. Synthesis method for anti-tumor compound and intermediate thereof
CN112939974B (zh) * 2021-03-11 2023-10-20 中山大学 一种氮杂苯并薁衍生物的制备方法
US20250082650A1 (en) * 2021-03-29 2025-03-13 Transthera Sciences (Nanjing), Inc. Combined use of multikinase inhibitor
WO2022237765A1 (zh) * 2021-05-10 2022-11-17 药捷安康(南京)科技股份有限公司 多激酶抑制剂的药物组合物及其用途
CN116236489A (zh) * 2021-12-07 2023-06-09 药捷安康(南京)科技股份有限公司 激酶抑制剂的新用途
CN114957081B (zh) * 2022-05-27 2024-04-05 中国科学院上海有机化学研究所 薁类化合物、其中间体、其制备方法及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1227555A (zh) * 1996-06-12 1999-09-01 日本烟草产业株式会社 细胞因子生成抑制剂、三氮䓬化合物及其中间体
CN102603743A (zh) * 2012-02-24 2012-07-25 南京天易生物科技有限公司 抗肿瘤的氮杂苯并[f]薁衍生物其制备方法及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0888292T3 (da) * 1996-03-20 2002-02-18 Genentech Inc Tricykliske forbindelser med virkning over for integriner, især alphavbeta3 integriner, fremgangsmåde til deres fremstilling, mellemprodukter deraf, deres anvendelse som lægemidler og farmaceutiske præparater med indhold deraf
US6440959B1 (en) * 1999-04-21 2002-08-27 Hoffman-La Roche Inc. Pyrazolobenzodiazepines
BRPI0518152A (pt) * 2004-10-13 2008-11-04 Hoffmann La Roche pirazolbenzodiazepinas dissubstituìdas úteis como inibidores para cdk2 e angiogênese e para o tratamento de cánceres de mama, cólon, pulmão e próstata
BRPI0617252A2 (pt) * 2005-10-14 2011-07-19 Hoffmann La Roche regime de administração para benzodiazepina 5-2-clorofenil)-1,2-diidro-7-flìor-8-metóxi-3-metil-pira zolo [3,4-b] [1,4]
MX2012006381A (es) * 2009-12-01 2012-06-19 Abbott Lab Nuevos compuestos triciclicos.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1227555A (zh) * 1996-06-12 1999-09-01 日本烟草产业株式会社 细胞因子生成抑制剂、三氮䓬化合物及其中间体
CN102603743A (zh) * 2012-02-24 2012-07-25 南京天易生物科技有限公司 抗肿瘤的氮杂苯并[f]薁衍生物其制备方法及其用途

Also Published As

Publication number Publication date
JP2015508083A (ja) 2015-03-16
EP2818171A4 (de) 2015-09-02
EP2818171B1 (de) 2016-12-28
US20150011536A1 (en) 2015-01-08
EP2818171A1 (de) 2014-12-31
CN102603743B (zh) 2014-05-28
ES2617965T3 (es) 2017-06-20
CN102603743A (zh) 2012-07-25
JP5851053B2 (ja) 2016-02-03
US9382249B2 (en) 2016-07-05

Similar Documents

Publication Publication Date Title
WO2013123840A1 (zh) 抗肿瘤的氮杂苯并[f]薁衍生物其制备方法及其用途
CA2736097C (en) Carbazole compounds for inhibition of nf-kb activity
JP2022518591A (ja) 複素環式化合物であるベンゾピリドンおよびその使用
JP7720661B2 (ja) ベンゾ［ｂ］セレノフェン系ＳＴＩＮＧ調節剤、その製造方法及び使用
CN109134586B (zh) 雷公藤红素衍生物及其应用
BR112017009012B1 (pt) Derivados de anel benzo de seis membros como inibidor de dpp-4 e uso dos mesmos
WO2013178021A1 (zh) 吡咯并[2，1—f][1，2，4]三嗪衍生物及其抗肿瘤用途
WO2013107428A1 (zh) 7-位取代的汉防己乙素衍生物、及其制备方法和应用
WO2018149231A1 (zh) 7H-吡咯并[2,3-d]嘧啶衍生物及抗肿瘤的应用
CN114605407B (zh) 一种吲哚喹啉酮类化合物及其合成方法和应用
TW202413326A (zh) Ｓｔａｔ３抑制劑的前藥
JP7620091B2 (ja) 縮合環ジイミド誘導体、その製造方法と使用
CN106957303A (zh) 选择性AuroraA激酶抑制活性的喹唑啉衍生物及其制备方法以及应用
CN107739381B (zh) 莪术醇衍生物及其在制备抗肿瘤药物中的应用
CN108047182B (zh) 一种西瑞香素衍生物及其应用
JP7535825B2 (ja) アミノコンブレタスタチン誘導体及びその応用
CN111892596B (zh) 含多氟吡唑结构的β-咔啉类化合物的制备和应用
TWI419894B (zh) ４-苯胺基呋喃［２，３－ｂ］喹啉衍生物，其製備方法以及包含有此等衍生物的藥學組成物
CN105017245A (zh) 一种咪唑并吡啶化合物及其制备方法和应用
US9499552B2 (en) Pyrazolo[1,5-A]pyrimidine derivative and use of anti-tumor thereof
CN109627169A (zh) No供体型大黄酸衍生物、其制备方法及医药用途
US8952033B2 (en) 4-anilinofuro[2,3-b]quinoline derivatives, their preparation processes, and pharmaceutical compositions comprising the same
CN104672213A (zh) 一种具有抗肿瘤活性的酰胺类化合物及其应用
CN110698380A (zh) 一种内酰胺衍生物及其制备方法与应用
JP2020531592A (ja) 重水素化インドールアミン２，３−ジオキシゲナーゼ阻害剤及びその使用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13751374

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2014557981

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 14380596

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2013751374

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2013751374

Country of ref document: EP